Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations

H. Bunten, W. J. Liang, D. J. Pounder, C. Seneviratne, D. Osselton

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and µ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.
    Original languageEnglish
    Pages (from-to)431-437
    Number of pages7
    JournalJournal of Analytical Toxicology
    Volume35
    Issue number7
    DOIs
    Publication statusPublished - Sep 2011

    Keywords

    • MU-OPIOID-RECEPTOR
    • SINGLE-NUCLEOTIDE POLYMORPHISM
    • GENDER-DIFFERENCES
    • DOPAMINE RELEASE
    • SEX-DIFFERENCES
    • ASSOCIATION
    • ALCOHOL
    • ABUSE
    • A118G
    • AMPHETAMINE

    Cite this

    Bunten, H. ; Liang, W. J. ; Pounder, D. J. ; Seneviratne, C. ; Osselton, D. / Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations. In: Journal of Analytical Toxicology. 2011 ; Vol. 35, No. 7. pp. 431-437.
    @article{b87a4a32690a4516a3d229e9af558ef8,
    title = "Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations",
    abstract = "Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and µ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.",
    keywords = "MU-OPIOID-RECEPTOR, SINGLE-NUCLEOTIDE POLYMORPHISM, GENDER-DIFFERENCES, DOPAMINE RELEASE, SEX-DIFFERENCES, ASSOCIATION, ALCOHOL, ABUSE, A118G, AMPHETAMINE",
    author = "H. Bunten and Liang, {W. J.} and Pounder, {D. J.} and C. Seneviratne and D. Osselton",
    year = "2011",
    month = "9",
    doi = "10.1093/anatox/35.7.431",
    language = "English",
    volume = "35",
    pages = "431--437",
    journal = "Journal of Analytical Toxicology",
    issn = "0146-4760",
    publisher = "Oxford University Press",
    number = "7",

    }

    Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations. / Bunten, H.; Liang, W. J.; Pounder, D. J. ; Seneviratne, C.; Osselton, D.

    In: Journal of Analytical Toxicology, Vol. 35, No. 7, 09.2011, p. 431-437.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations

    AU - Bunten, H.

    AU - Liang, W. J.

    AU - Pounder, D. J.

    AU - Seneviratne, C.

    AU - Osselton, D.

    PY - 2011/9

    Y1 - 2011/9

    N2 - Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and µ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.

    AB - Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and µ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.

    KW - MU-OPIOID-RECEPTOR

    KW - SINGLE-NUCLEOTIDE POLYMORPHISM

    KW - GENDER-DIFFERENCES

    KW - DOPAMINE RELEASE

    KW - SEX-DIFFERENCES

    KW - ASSOCIATION

    KW - ALCOHOL

    KW - ABUSE

    KW - A118G

    KW - AMPHETAMINE

    U2 - 10.1093/anatox/35.7.431

    DO - 10.1093/anatox/35.7.431

    M3 - Article

    VL - 35

    SP - 431

    EP - 437

    JO - Journal of Analytical Toxicology

    JF - Journal of Analytical Toxicology

    SN - 0146-4760

    IS - 7

    ER -